Compare Abeona Therapeutics Inc (ABEO) vs Firy Inc. (FIRY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Firy Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Firy Inc. trades at $9.14 (market cap $143.59M). The key difference: Abeona Therapeutics Inc is far larger — about 2.6× Firy Inc.'s market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | FIRY | |
|---|---|---|
Market Cap | $373.32M | $143.59M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $12.45 |
52-Week Low | $4.17 | $2.28 |
Enterprise Value | $228.22M | $87.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FIRY, formerly Skillz Inc., trades at $9.20, down 5.54% today, amid a recent rebranding and mixed quarterly results. The stock shows a bullish technical signal with strong moving average support, while fundamentals reveal persistent losses despite a high gross margin of 87.75%. Revenue has declined from $270M in 2022 to $104M in 2025, with net income margins deeply negative. Cash flow remains negative, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; the company's cost structure and profitability challenges pose significant risks, offset by potential from legal victories and strategic shifts. Analysts are mostly neutral, with 60% hold ratings. Investors should weigh the high execution risk against any turnaround prospects in the competitive mobile gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
